吸入用布地奈德混懸液聯(lián)合硫酸特布他林霧化液治療慢性阻塞性肺疾病急性加重期的效果

趙楠

[摘要]目的 探討吸入用布地奈德混懸液聯(lián)合硫酸特布他林霧化液治療慢性阻塞性肺疾病急性加重期的效果。方法 選取2019年1～12月我院收治的88例慢性阻塞性肺疾病急性加重期患者作為研究對象，按照奇偶分組法將其分為觀察組和參照組，每組各44例。參照組采用吸入用布地奈德混懸液治療，觀察組在參照組的基礎(chǔ)上采用硫酸特布他林霧化液治療。比較兩組的臨床療效、治療前后肺功能指標(biāo)以及血清指標(biāo)。結(jié)果 觀察組的治療總有效率高于參照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的第1秒用力呼氣容積（FEV1）、用力肺活量（FVC）、第1秒用力呼氣量占用力肺活量比值（FEV1/FVC）均高于治療前，且觀察組的FEV1、FVC、FEV1/FVC均高于參照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的降鈣素原（PCT）、白細(xì)胞介素-6（IL-6）、γ干擾素（IFN-γ）均低于治療前，且觀察組的PCT、IL-6、IFN-γ均低于參照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 慢性阻塞性肺疾病急性加重期患者接受吸入用布地奈德混懸液聯(lián)合硫酸特布他林霧化液治療，能夠顯著改善患者的肺部功能和血清指標(biāo)水平，提高疾病治療效果，應(yīng)用價值較高。

[關(guān)鍵詞]慢性阻塞性肺疾病急性加重期;吸入用布地奈德混懸液;硫酸特布他林霧化液;臨床效果

[中圖分類號] R563.9 ? ? ? ? ?[文獻(xiàn)標(biāo)識碼] A ? ? ? ? ?[文章編號] 1674-4721（2020）9（c）-0054-04

[Abstract] Objective To investigate the effect of Inhaled Budesonide Suspension combined with Terbutaline Sulfate Solution for Nebulization in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods A total of 88 cases of patients with acute exacerbation of chronic obstructive pulmonary disease treated in our hospital from January to December 2019 were selected as the research objects， and divided into the observation group and the reference group by even and odd grouping method， with 44 cases in each group. The reference group was treated with Inhaled Budesonide Suspension， and the observation group was treated with Terbutaline Sulfate Solution for Nebulization on the basis of the reference group. The clinical efficacy， lung function indexes and serum indexes before and after treatment were compared between the two groups. Results The total effective rate of treatment of the observation group was higher than that of the reference group， and the difference was statistically significant （P<0.05）. The forced expiratory volume in the first second （FEV1）， forced vital capacity （FVC） and the ratio of forced expiratory volume in the first second to forced vital capacity （FEV1/FVC） after treatment in two groups were higher than those before treatment， and the FEV1， FVC and FEV1/FVC in observation group were higher than those in the reference group， and the differences were statistically significant （P<0.05）. The procalcitonin （PCT）， interleukin-6 （IL-6）， and interferon-γ （IFN-γ） after treatment in the two groups were lower than those before treatment， and the PCT， IL-6， and IFN-γ in the observation group were lower than those in the reference group， and the differences were statistically significant （P<0.05）. Conclusion Patients with acute exacerbation of chronic obstructive pulmonary disease receive Inhaled Budesonide Suspension combined with Terbutaline Sulfate Solution for Nebulization can significantly improve patients′ lung function and serum indicators， improve the treatment effect of the disease， and have higher application value.

[Key words] Acute exacerbation of chronic obstructive pulmonary disease; Inhaled Budesonide Suspension; Terbutaline Sulfate Solution for Nebulization; Clinical effect

慢性阻塞性肺疾病是臨床上常見的呼吸道疾病，是一種以不完全可逆性氣流受限為特征的疾病，對患者的呼吸功能造成較大影響[1]。當(dāng)慢性阻塞性肺疾病患者的病情得不到有效的控制，或者受到病毒、細(xì)菌感染后，會出現(xiàn)病情加重的現(xiàn)象，對于慢性阻塞性肺疾病急性加重期患者，其呼吸道受到更為嚴(yán)重的損傷，患者多會出現(xiàn)咳嗽次數(shù)增多、痰量增加、呼吸困難等癥狀，對患者的身心健康和生命安全有造成較大威脅[2-3]。臨床在治療慢性阻塞性肺疾病急性加重期時，會根據(jù)患者的病情實(shí)施合理的治療，以抑制呼吸道炎性反應(yīng)，改善患者的呼吸功能[4]。糖皮質(zhì)激素是對患者治療的常用藥物，具有明顯的效果，臨床應(yīng)用時為了提高治療效果，多會采用糖皮質(zhì)激素聯(lián)合其他藥物治療[5]?！?br>